ICU
SeaStar Medical Holding Corporation
NASDAQ · Healthcare · Biotechnology · US
$2.96
+1.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7M | 1.2M | 135.0K | — | — |
| Cost of Revenue | 126.0K | 53.0K | — | — | — |
| Gross Profit | 1.6M | 1.2M | 135.0K | — | — |
| Operating Expenses | |||||
| R&D Expense | 8.9M | 7.5M | 9.1M | 6.0M | 2.5M |
| SG&A Expense | 6.7M | 5.8M | 8.9M | 8.0M | 6.9M |
| General & Admin Expense | 6.7M | 5.8M | 8.9M | 8.0M | 6.9M |
| Selling & Marketing Expense | — | — | — | 32.0K | — |
| Other Expenses | — | — | — | 200.0K | 2.2M |
| Total Operating Expenses | 15.6M | 13.4M | 18.0M | 14.2M | 11.6M |
| Cost and Expenses | 15.7M | 13.4M | 18.0M | 14.2M | 11.6M |
| Operating Income (EBIT) | (14.0M) | (12.2M) | (17.8M) | (14.2M) | (11.6M) |
| Non-Operating | |||||
| Interest Income | 392.0K | 325.0K | 101.0K | — | 630.00 |
| Interest Expense | 27.0K | 329.0K | 244.0K | 1.1M | 630.0K |
| Net Interest Income | 365.0K | (4.0K) | (143.0K) | (1.1M) | (629.0K) |
| Other Non-Op Income/Expense | 365.0K | 28.0K | (7.0M) | (12.0M) | (580.0K) |
| Non-Operating Income (excl Interest) | (301.0K) | — | 6.7M | 10.9M | (50.0K) |
| EBT (Pre-Tax Income) | (13.6M) | (12.1M) | (24.8M) | (26.2M) | (12.2M) |
| Income Tax Expense | 3.0K | 3.0K | 3.0K | — | 1.0K |
| Bottom Line | |||||
| Net Income | (13.6M) | (12.2M) | (24.8M) | (26.2M) | (12.2M) |
| Earnings from Cont. Ops | (13.6M) | (12.2M) | (24.8M) | (26.2M) | (12.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (13.6M) | (12.2M) | (24.8M) | (26.2M) | (12.2M) |
| Per Share | |||||
| Basic EPS | ($3.91) | ($5.86) | ($66.30) | ($302.62) | ($233.80) |
| Diluted EPS | ($3.91) | ($5.86) | ($66.30) | ($302.62) | ($233.80) |
| Revenue Per Share | $0.42 | $0.06 | $0.36 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.1M | 20.7M | 374400 | 86681 | 52132 |
| Diluted Shares Outstanding | 4.1M | 20.7M | 374400 | 86681 | 52134 |
| Profitability Metrics | |||||
| EBITDA | (13.7M) | (12.2M) | (24.6M) | (11.1M) | (11.6M) |
| D&A | 27.0K | 18.0K | — | 14.0M | — |
| EBIT | (13.7M) | (12.2M) | (24.6M) | (25.2M) | (11.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026